Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors

References

• BarnardLLavoieDLajeunesseNIncrease in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concernDrug Saf200629761362016808553
   PubMed Web of Science ®Google Scholar
• RoumieCLArbogastPGMitchelEFJrGriffinMRPrescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerousJ Gen Intern Med2005201087988316191131
   PubMed Web of Science ®Google Scholar
• GarciaRLJickHRisk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugsLancet199434389007697727907735
   PubMed Web of Science ®Google Scholar
• DerrySLokeYKRisk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysisBMJ200032172701183118711073508
   PubMed Web of Science ®Google Scholar
• RostomAWellsGTugwellPWelchVDubeCMcGowanJThe prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trialsJ Rheumatol20002792203221410990235
   PubMed Web of Science ®Google Scholar
• RostomADubéCJolicoeurEBoucherMJoyceJ Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Technology report no 37. 2003. Ottawa, Canadian Coordinating Office for Health Technology Assessment.
   Google Scholar
• RostomAMoayyediPHuntRSystematic Review: Canadian Consensus guidelines on long-term NSAID therapy and the need for gastroprotectionAliment Pharmacol Ther200929548149619053986
   PubMed Web of Science ®Google Scholar
• LanasABaronJASandlerRSPeptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trialGastroenterology2007132249049717258718
   PubMed Web of Science ®Google Scholar
• BaronJASandlerRSBresalierRSA randomized trial of rofecoxib for the chemoprevention of colorectal adenomasGastroenterology200613161674168217087947
   PubMed Web of Science ®Google Scholar
• RostomAMuirKDubeCGastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic reviewClin Gastroenterol Hepatol20075781882817556027
   PubMed Web of Science ®Google Scholar
• KearneyPMBaigentCGodwinJHallsHEmbersonJPatronoCDo selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of athero-thrombosis? Meta-analysis of randomised trialsBMJ20063321302130816740558
   PubMed Web of Science ®Google Scholar
• McGettiganPHenryDCardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2JAMA2006296131633164416968831
   PubMed Web of Science ®Google Scholar
• StupnickiTDietrichKGonzalez-CarroPEfficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patientsDigestion200368419820814707396
   PubMed Web of Science ®Google Scholar
• MeloGARothSHZeehJBruynGAWoodsEMGeisGSDouble-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritisAnn Rheum Dis199352128818858311540
   PubMed Web of Science ®Google Scholar
• WatsonDJRahmeESantanelloNCIncrease in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concernDrug Saf2007301899017194174
   PubMed Web of Science ®Google Scholar
• HigginsJGreenS Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. Higgins J, Green S, editors. The Cochrane Collaboration. 2008. The Cochrane Collaboration.
   Google Scholar
• RostomAWellsGTugwellPWelchVDubeCMcGowanJPrevention of NSAID-induced gastroduodenal ulcers [update of Cochrane Database Syst Rev. 2000;(3):CD002296; 10908548.].Cochrane Database Syst Rev20024CD00229612519573
   PubMedGoogle Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• SchulzKChalmersIHayesRAltmanDEmperical evidence of bias: dimension of the methodological quality associated with estimates of treatment effects in controlled trialsJAMA19952734084127823387
   PubMed Web of Science ®Google Scholar
• PetittiDApproaches to heterogeneity in meta-analysisStat Med20012023224233
   Web of Science ®Google Scholar
• AgrawalNMRothSGrahamDYMisoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trialAnn Intern Med199111531952001905501
   PubMed Web of Science ®Google Scholar
• AgrawalNMVanKHErhardtLJGeisGSMisoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year studyDig Dis Sci1995405112511317729275
   PubMed Web of Science ®Google Scholar
• BocanegraTSWeaverALTindallEADiclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study GroupJ Rheumatol1998258160216119712107
   PubMed Web of Science ®Google Scholar
• BoltenWGomesJASteadHGeisGSThe gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritisBr J Rheumatol199231117537581450797
   PubMedGoogle Scholar
• ChanFKSungJJChingJYRandomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugsAliment Pharmacol Ther2001151192411136274
   PubMed Web of Science ®Google Scholar
• ChandrasekaranANSambandamPRLalHMDouble blind, placebo controlled trial on the cytoprotective effect of misoprostol in subjects with rheumatoid arthritis, osteoarthritis and seronegative spondarthropathy on NSAIDsJ Assoc Physicians India199139129199211816217
   PubMedGoogle Scholar
• Cohen de LaraAGompelHBaranesCTwo comparative studies of dosmalfate vs misoprostol in the prevention of NSAID-induced gastric ulcers in rheumatic patientsDrugs Today200036Suppl A7378
   Google Scholar
• DelmasPDLambertRCapronMHMisoprostol in the prevention of gastric erosions caused by nonsteroidal anti-inflammatory agentsRevue du Rhumatisme1994 Edition(2):1261317920500
   PubMedGoogle Scholar
• ElliottSLYeomansNDBuchananRRSmallwoodRAEfficacy of 12 months’ misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trialScand J Rheumatol19942341711768091141
   PubMed Web of Science ®Google Scholar
• GrahamDYAgrawalNMRothSHPrevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trialLancet198828623127712802904006
   PubMed Web of Science ®Google Scholar
• GrahamDYWhiteRHMorelandLWDuodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study GroupAnn Intern Med199311942572628328732
   PubMed Web of Science ®Google Scholar
• GrahamDYAgrawalNMCampbellDRUlcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazoleArch Intern Med2002162216917511802750
   PubMed Web of Science ®Google Scholar
• HawkeyCJKarraschJASzczepanskiLOmeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study GroupN Engl J Med1998338117277349494149
   PubMed Web of Science ®Google Scholar
• HenrikssonKUribeASandstedtBNordCEHelicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritisDig Dis Sci1993389168816968359082
   PubMed Web of Science ®Google Scholar
• JensenDMHoSHamamahSA randomized study of omeprazole compared to misoprostol for prevention of recurrent ulcers and ulcer hemorrhage in high risk patients ingesting aspirin or NSAIDs [abstract]Gastroenterology20001184 Suppl 2 Pt 1 AGA A892
   Web of Science ®Google Scholar
• RaskinJBWhiteRHJacksonJEMisoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimensAnn Intern Med199512353443507625622
   PubMed Web of Science ®Google Scholar
• RaskinJBWhiteRHJaszewskiRKorstenMASchubertTTFortJGMisoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter studyAm J Gastroenterol19969122232278607484
   PubMed Web of Science ®Google Scholar
• RothSHTindallEAJainAKA controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosaArch Intern Med199315322256525718239849
   PubMedGoogle Scholar
• SaggioroAAlvisiVBlasiADobrillaGFioravantiAMarcolongoRMisoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoarthritis and rheumatoid arthritisItal J Gastroenterol1991233119123 Erratum in Ital J Gastroenterol. 1991;23(5):273.1742504
   PubMedGoogle Scholar
• SilversteinFEGrahamDYSeniorJRMisoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trialAnn Intern Med199512342412497611589
   PubMed Web of Science ®Google Scholar
• ValentiniMCannizzaroRPolettiMNonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damageJ Clin Oncol19951310263726427595718
   PubMed Web of Science ®Google Scholar
• VerdicktWMoranCHantzschelHFragaAMSteadHGeisGSA double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritisScand J Rheumatol199221285911570496
   PubMed Web of Science ®Google Scholar
• BerkowitzJMRogenesPRSharpJTWarnerCWRanitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapyArch Intern Med198714712213721393689065
   PubMedGoogle Scholar
• EhsanullahRSPageMCTildesleyGWoodJRPrevention of gastro-duodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidineBMJ19882976655101710213142593
   PubMed Web of Science ®Google Scholar
• RobinsonMMillsRJEulerARRanitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapyAliment Pharmacol Ther1991521431501832313
   PubMed Web of Science ®Google Scholar
• RobinsonMGGriffinJJBowersJEffect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflam-matory drugsDig Dis Sci19893434244282646087
   PubMed Web of Science ®Google Scholar
• TahaASHudsonNHawkeyCJFamotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugsN Engl J Med199633422143514398618582
   PubMed Web of Science ®Google Scholar
• Van GroenendaelJHMarkusseHMDijkmansBABreedveldFCThe effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritisClin Rheumatol19961554504568894357
   PubMed Web of Science ®Google Scholar
• LevineLRCloudMLEnasNHNizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugsArch Intern Med199315321244924548215749
   PubMedGoogle Scholar
• SwiftGLHeneghanMWilliamsGTWilliamsBDO’SullivanMMRhodesJEffect of ranitidine on gastroduodenal mucosal damage in patients on long-term non-steroidal anti-inflammatory drugsDigestion198944286942693162
   PubMed Web of Science ®Google Scholar
• SimonBMullerPNizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patientsScand J Gastroenterol Suppl199420625287863248
   PubMedGoogle Scholar
• HudsonNTahaASRussellRIFamotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulcerationGastroenterology19971126181718229178671
   PubMed Web of Science ®Google Scholar
• WoldeSDijkmansBAJanssenMHermansJLamersCBHigh-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDsAliment Pharmacol Ther19961033473518791962
   PubMed Web of Science ®Google Scholar
• Bianchi PorroGLazzaroniMImbesiVMontroneFSantagadaTEfficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group studyDig Liver Dis200032320120810975769
   PubMedGoogle Scholar
• CullenDBardhanKDEisnerMPrimary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug usersAliment Pharmacol Ther19981221351409692687
   PubMed Web of Science ®Google Scholar
• EkstromPCarlingLWetterhusSPrevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre studyScand J Gastroenterol19963187537588858742
   PubMed Web of Science ®Google Scholar
• LaiKCLamSKChuKMLansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users – a randomized trialAliment Pharmacol Ther200318882983614535877
   PubMed Web of Science ®Google Scholar
• YeomansNDTulassayZJuhaszLRaczIHowardJA comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugsN Eng J Med199833811719726
   PubMed Web of Science ®Google Scholar
• FDA – Study 21-Celebrex. Available from http://www.fda.gov/cder/foi/adcomm/98/celebrex.htm). Accessed Aug 31, 2009.
   Google Scholar
• FDA – Study 71-Celebrex. Available from http://www.fda.gov/cder/foi/adcomm/98/celebrex.htm. Accessed Aug 31, 2009.
   Google Scholar
• FDA – Study 47-FDA Review (ND21-341) – Bextra. Available from http://www.fda.gov/cder/foi/nda/2001/21-341_Bextra.htm. Accessed Aug 31, 2009.
   Google Scholar
• FDA – Study 61-FDA Drug Review (ND21-341) – Bextra. Available from http://www.fda.gov/cder/foi/nda/2001/21-341_Bextra.htm. Accessed Aug 31, 2009.
   Google Scholar
• FDA – Study 63-FDA Drug Review (ND21-341) – Bextra. Available from http://www.fda.gov/cder/foi/nda/2001/21-341_Bextra.htm). Accessed Aug 31, 2009.
   Google Scholar
• GoldsteinJLSilversteinFEAgrawalNMReduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitorAm J Gastroenterol20009571681169010925968
   PubMed Web of Science ®Google Scholar
• GoldsteinJLEisenGMAgrawalNStensonWFKentJDVerburgKMReduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxibAliment Pharmacol Ther200420552753815339324
   PubMed Web of Science ®Google Scholar
• LangmanMJJensenDMWatsonDJAdverse upper gastrointestinal effects of rofecoxib compared with NSAIDsJAMA1999282201929193310580458
   PubMed Web of Science ®Google Scholar
• DistelMMuellerCBluhmkiEGlobal analysis of gastrointestinal safety of a new NSAID, meloxicamInflammopharmacology1996417181
   Google Scholar
• RameyDRWatsonDJYuCBologneseJACurtisSPReicinASThe incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs non-selective NSAIDs: An updated combined analysisCurr Med Res Opin200521571572215974563
   PubMed Web of Science ®Google Scholar
• GoldsteinJLCorreaPZhaoWWReduced incidence of gastro-duodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritisAm J Gastroenterol20019641019102711316141
   PubMed Web of Science ®Google Scholar
• EmeryPZeidlerHKvienTKCelecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparisonLancet199935491962106211110609815
   PubMed Web of Science ®Google Scholar
• SimonLSWeaverALGrahamDYAnti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.[see comment]JAMA1999282201921192810580457
   PubMed Web of Science ®Google Scholar
• LaineLHarperSSimonTA randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study GroupGastroenterology1999117477678310500058
   PubMed Web of Science ®Google Scholar
• HawkeyCLaineLSimonTComparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study GroupArthritis Rheum200043237037710693877
   PubMed Web of Science ®Google Scholar
• HawkeyCJLaineLSimonTIncidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind studyGut2003526820826 erratum in Gut. 2003;52(12):1800.12740337
   PubMed Web of Science ®Google Scholar
• HawkeyCCSvobodaPFiedorowicz-FabrycyIFGastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritisJ Rheumatol20043191804181015338504
   PubMed Web of Science ®Google Scholar
• SikesDHAgrawalNMZhaoWWKentJDReckerDPVerburgKMIncidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritisEur J Gastroenterol Hepatol200214101101111112362101
   PubMed Web of Science ®Google Scholar
• PavelkaKReckerDPVerburgKMValdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trialRheumatology200342101207121512810937
   PubMed Web of Science ®Google Scholar
• HuntRHHarperSWatsonDJThe gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal eventsAm J Gastroenterol20039881725173312907325
   PubMed Web of Science ®Google Scholar
• HuntRHHarperSCallegariPComplementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxibAliment Pharmacol Ther200317220121012534404
   PubMed Web of Science ®Google Scholar
• KivitzAEisenGZhaoWWBevirtTReckerDPRandomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritisJ Fam Pract200251653053712100776
   PubMed Web of Science ®Google Scholar
• KivitzAJNayiagerSSchimanskyTGimonaAThurstonHJHawkeyCReduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritisAliment Pharmacol Ther200419111189119815153172
   PubMed Web of Science ®Google Scholar
• SilversteinFEFaichGGoldsteinJLGastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety StudyJAMA2000284101247125510979111
   PubMed Web of Science ®Google Scholar
• BombardierCLaineLReicinAComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupN Engl J Med2000343211520152811087881
   PubMed Web of Science ®Google Scholar
• DequekerJHawkeyCKahanAImprovement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritisBr J Rheumatol19983799469519783758
   PubMedGoogle Scholar
• HawkeyCKahanASteinbruckKGastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety AssessmentBr J Rheumatol1998379937945 erratum in Br J Rheumatol. 1998; 37(10):1142.9783757
   PubMedGoogle Scholar
• SchnitzerTJFrickeJJrGittonXJayawardeneSSloanVSLumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: Results of three dose-response studiesCurr Med Res Opin200521115116115881487
   PubMed Web of Science ®Google Scholar
• LeungATMalmstromKGallacherAEEfficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trialCurr Med Res Opin2002182495812017209
   PubMed Web of Science ®Google Scholar
• LisseJRPerlmanMJohanssonGGastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trialAnn Intern Med2003139753954614530224
   PubMed Web of Science ®Google Scholar
• ZhaoSZMcMillenJIMarkensonJAEvaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxibPharmacotherapy199919111269127810555933
   PubMed Web of Science ®Google Scholar
• GeusensPPTruittKSfikakisPA placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritisScand J Rheumatol200231423023812369656
   PubMed Web of Science ®Google Scholar
• SinghGFortJGGoldsteinJLCelecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I StudyAm J Med2006119325526616490472
   PubMed Web of Science ®Google Scholar
• GoldsteinJLSilversteinFEAgrawalNMReduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitorAm J Gastroenterol20009571681169010925968
   PubMed Web of Science ®Google Scholar
• YocumDFleischmannRDalginPCaldwellJHallDRoszkoPSafety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis InvestigatorsArch Intern Med2000160192947295411041902
   PubMed Web of Science ®Google Scholar
• WilliamsGW ERREHRLMYSZTreatment of osteoarthritis with a once-daily dosing regimen of celecoxib: A randomized, controlled trialJ Clin Rheumatol200062657419078452
   PubMed Web of Science ®Google Scholar
• BensenWGFiechtnerJJMcMillenJITreatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trialMayo Clin Proc199974111095110510560596
   PubMed Web of Science ®Google Scholar
• TruittKESperlingRSEttingerWHJrA multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritisAging Clin Exp Res2001132112121
   Web of Science ®Google Scholar
• DayRMorrisonBLuzaAA randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study GroupArch Intern Med2000160121781178710871971
   PubMedGoogle Scholar
• CannonGWCaldwellJRHoltPRofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study GroupArthritis Rheum200043597898710817549
   PubMed Web of Science ®Google Scholar
• EhrichEWSchnitzerTMMcIlwainHEffect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double-blind, placebo controlled pilot study of rofecoxibJ Rheumatol199926112438244710555907
   PubMed Web of Science ®Google Scholar
• SchnitzerTJTruittKFleischmannRThe safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritisClin Ther199921101688170210566565
   PubMed Web of Science ®Google Scholar
• SaagKvan derHDFisherCRofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies GroupArch Fam Med20009101124113411115219
   PubMedGoogle Scholar
• GebaGPWeaverALPolisABDixonMESchnitzerTJVioxxACTVGEfficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trialJAMA200228716471 erratum in JAMA. 200227;287(8):989.11754710
   PubMed Web of Science ®Google Scholar
• WheltonACyclooxygenase-2 – specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patientsAm J Ther200182859511304662
   PubMedGoogle Scholar
• McKennaFBorensteinDWendtHWallemarkCLefkowithJBGeisGSCelecoxib versus diclofenac in the management of osteoarthritis of the kneeScand J Rheumatol2001301111811252686
   PubMed Web of Science ®Google Scholar
• McKennaFCOX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled, randomized, double-blind studyJ Clin Rheumatol20017315115917039120
   PubMed Web of Science ®Google Scholar
• MakarowskiWZhaoWWBevirtTReckerDPEfficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxenOsteoarthritis Cartilage200210429029611950252
   PubMed Web of Science ®Google Scholar
• BensenWWeaverAEspinozaLEfficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxenRheumatology20024191008101612209034
   PubMed Web of Science ®Google Scholar
• GottesdienerKSchnitzerTFisherCResults of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritisRheumatology (Oxford)200241910521061 Erratum in Rheumatology (Oxford). 2003;42(6):814.12209041
   PubMed Web of Science ®Google Scholar
• ZacherJFeldmanDGerliRA comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritisCurr Med Res Opin2003198725736 Erratum in Curr Med Res Opin. 2004;20(10):1689.14687444
   PubMed Web of Science ®Google Scholar
• CollantesECurtisSPLeeKWA multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]BMC Fam Pract2002311012033987
   PubMedGoogle Scholar
• MatsumotoAKMelianAMandelDRA randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritisJ Rheumatol20022981623163012180720
   PubMed Web of Science ®Google Scholar
• KivitzAJNayiagerSSchimanskyTGimonaAThurstonHJHawkeyCReduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritisAliment Pharmacol Ther200419111189119815153172
   PubMed Web of Science ®Google Scholar
• HawkeyCCSvobodaPFiedorowicz-FabrycyIFGastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritisJ Rheumatol20043191804181015338504
   PubMed Web of Science ®Google Scholar
• SchnitzerTJBurmesterGRMyslerEComparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialLancet2004364943566567415325831
   PubMed Web of Science ®Google Scholar
• GoldsteinJLAgrawalNEisenG Significantly improved upper gastrointestinal (UGI) tolerability with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDS. The Success-1 trial [abstract]. Abstracts in Perspective 5[1]2001
   Google Scholar
• LaineLCurtisSPCryerBKaurACannonCPAssessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonLancet2007369956046547317292766
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration Arthritis Drugs Advisory Committee Meeting 12/1/1998. CLASS – 12 Month Data. 1998. Available from.
   Google Scholar
• ChanFKHungLCSuenBYCelecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trialGastroenterology200412741038104315480981
   PubMed Web of Science ®Google Scholar
• LaiKCChuKMHuiWMCelecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complicationsAm J Med2005118111271127816271912
   PubMed Web of Science ®Google Scholar
• ChanFKWongVWSuenBYCombination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trialLancet200736995731621617499604
   PubMed Web of Science ®Google Scholar
• Myllykangas-LuosujarviRLuHSChenSLComparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trals of six weeks durationScand J Rheumatol200231633734412492248
   PubMed Web of Science ®Google Scholar
• KivitzAJMoskowitzRWWoodsEComparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hipJ Int Med Res200129646747911803730
   PubMed Web of Science ®Google Scholar
• WiesenhutterCWBoiceJAKoAEvaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trialMayo Clin Proc200580447047915819283
   PubMed Web of Science ®Google Scholar
• GeusensPAltenRRovenskyJEfficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritisInt J Clin Pract200458111033104115605667
   PubMed Web of Science ®Google Scholar
• GrifkaJKZacherJBrownJPEfficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the handClin Exp Rheumatol200422558959615485012
   PubMed Web of Science ®Google Scholar
• LehmannRBrzoskoMKopsaPEfficacy and tolerability of lumiracoxib 100mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxibCurr Med Res Opin200521451752615899100
   PubMed Web of Science ®Google Scholar
• LaineLMallerESYuCQuanHSimonTUlcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trialGastroenterology2004127239540215300570
   PubMed Web of Science ®Google Scholar
• Catella-LawsonFReillyMPKapoorSCCyclooxygenase inhibitors and the antiplatelet effects of aspirinN Engl J Med2001345251809181711752357
   PubMed Web of Science ®Google Scholar
• OuelletMRiendeauDPercivalMDA high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirinProc Natl Acad Sci U S A20019825145831458811717412
   PubMed Web of Science ®Google Scholar
• BaigentCPatronoCSelective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisalArthritis Rheum2003481122012528099
   PubMed Web of Science ®Google Scholar
• PatronoCAspirin resistance: definition, mechanisms and clinical read-outsJ Thromb Haemost2003181710171312911581
   PubMed Web of Science ®Google Scholar
• CipolloneFRoccaBPatronoCCyclooxygenase-2 expression and inhibition in atherothrombosisArterioscler Thromb Vasc Biol200424224625514592854
   PubMed Web of Science ®Google Scholar
• KhanNAMcAlisterFARabkinSWThe 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – TherapyCan J Cardiol200622758359316755313
   PubMed Web of Science ®Google Scholar
• PearsonTABlairSNDanielsSRAHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating CommitteeCirculation2002106338839112119259
   PubMed Web of Science ®Google Scholar
• RostomAMoayyediPHuntRfor the Canadian Association of Gastroenterology Consensus groupCanadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risksAliment Pharmacol Ther200929548149619053986
   PubMed Web of Science ®Google Scholar
• ChanFKChungSCSuenBYPreventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxenN Engl J Med20013441396797311274623
   PubMed Web of Science ®Google Scholar
• VergaraMCatalanMGisbertJPCalvetXMeta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID usersAliment Pharmacol Ther200521121411141815948807
   PubMed Web of Science ®Google Scholar
• LabenzJBlumALBoltenWWPrimary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trialGut200251332933512171952
   PubMed Web of Science ®Google Scholar
• HuntRFalloneCVeldhuyzan vanZSCanadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori–an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infectionCan J Gastroenterol200418954755415457293
   PubMed Web of Science ®Google Scholar
• RothSHBennettREMitchellCSHartmanRJCimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluationArch Intern Med198714710179818013310942
   PubMedGoogle Scholar
• TannenbaumHBerenbaumFReginsterJYLumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxibAnn Rheum Dis200463111419142615020310
   PubMed Web of Science ®Google Scholar
• WilliamsGHubbardRYuSS ZComparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the kneeClin Ther200123221322711293555
   PubMed Web of Science ®Google Scholar